Article info

Download PDFPDF
Randomised controlled trial
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding
  1. Correspondence to: Renato D Lopes
    Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Durham, NC 27705, USA; renato.lopes{at}duke.edu
View Full Text

Citation

Lopes RD, Garcia DA
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

Publication history

  • First published July 29, 2011.
Online issue publication 
November 20, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.